ArticleThoracic cancer2021
Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples.
Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Tumor Cell Count and Total Cell Count as Surrogate Indicators of Comprehensive Genomic Profiling Success in Pancreatic Cancer Specimens Collected by Endoscopic Ultrasonography-Guided Tissue Acquisition.Journal of hepato-biliary-pancreatic sciences · 2026Article
- Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421L.ESMO open · 2026Observational
- Prospective multicenter validation of a next-generation sequencing panel using cytology specimens for lung cancer: cPANEL.BMC cancer · 2025Article
- Tumor Cell Proportion Assessment in Advanced Non-Squamous Non-Small Cell Lung Cancer Tissue Samples in Real-World Settings in Japan: The ASTRAL Study.Diagnostics (Basel, Switzerland) · 2025Article
- Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.Thoracic cancer · 2025Article
- Bronchoscope Size Selection for Improved Diagnostic Yield in Peripheral Pulmonary Lesions: A Retrospective Study.Cureus · 2025Article
- Improving diagnostic capabilities in lung cancer through next-generation sequencing: a narrative review.Journal of thoracic disease · 2025Review
- Companion Diagnostics (CDx) Based on Molecular Biology Techniques.Life (Basel, Switzerland) · 2024Review
- Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.Scientific reports · 2024Article
- Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.Cancer medicine · 2024Article
- Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.JCO precision oncology · 2024Article
- Evaluation of appropriate conditions for Oncomine DxTT testing of FFPE specimens for driver gene alterations in non-small cell lung cancer.Thoracic cancer · 2023Article
- Nucleic Acid Quality Assessment is Critical to the Success of the Oncomine Dx Target Test for Lung Cancer.Molecular diagnosis & therapy · 2023Article
- Analytical Performance of a Highly Sensitive System to Detect Gene Variants Using Next-Generation Sequencing for Lung Cancer Companion Diagnostics.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.Thoracic cancer · 2022Article
- Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer.BMC pulmonary medicine · 2022Article
- Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.Cancer science · 2022Article
- Comparison of the efficiency of endobronchial ultrasound-guided transbronchial needle aspiration using a 22G needle versus 25G needle for the diagnosis of lymph node metastasis in patients with lung cancer: a prospective randomized, crossover study.Translational lung cancer research · 2021Article
- Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Oncomine Dx Target Test (ODxTT) is a next-generation sequencing-based companion diagnostic test which has been recently developed; however, its analysis success rate could be improved, especially for small samples. The aim of this study was to identify the pathological factors associated with biopsy specimens that affect the analysis success rate of ODxTT.
methodsWe retrospectively investigated 119 cases subjected to ODxTT at Kanagawa Cancer Center. Data pertaining to the results of BRAF V600E mutation analysis in ODxTT and pathological factors based on microscope slides were collected. Pathological factors including tissue surface area, tumor cell count, and tumor content rate were assessed. We constructed receiver operating characteristic curves and determined the optimal cutoff values of each pathological factor. Multivariate logistic analysis was used to identify significant factors.
resultsA total of 98 of 119 samples were successfully analyzed (75.6%). The tissue surface area and tumor cell count were significantly higher in the group associated with analysis success (P < 0.001 and P = 0.011, respectively), and their optimal cutoff values were 1.04 mm
conclusionsSelecting samples with a tissue surface area > 1.04 mm KEY POINTS: Significant findings of the study: We found that a tissue surface area > 1.04 mm WHAT THIS STUDY ADDS: It is sometimes necessary to assess genetic alterations with a small biopsy sample in daily practice. The criteria mentioned above will help to determine which tests should be performed, ODxTT or multiple single-gene testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.